bell
The current prices are delayed by 15 mins, login to check live prices.
Alembic Pharmaceuticals Ltd share price logo

Alembic Pharmaceuticals Ltd

(APLLTD)

₹1055.15▲0.7%

as on 04:01PM, 20 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Alembic Pharmaceuticals Ltd Analyst Rating

based on 12 analysts

HOLD

38.46%

Buy

38.46%

Hold

23.08%

Sell

Based on 12 analysts offering long term price targets for Alembic Pharmaceuticals Ltd. An average target of ₹1161.92

Source: S&P Global Market Intelligence

Alembic Pharmaceuticals Ltd Share analysis

Alembic Pharmaceuticals Ltd price forecast by 12 analysts

Upside of10.89%

High

₹1412

Target

₹1161.92

Low

₹895

Alembic Pharmaceuticals Ltd target price ₹1161.92, a slight upside of 10.89% compared to current price of ₹1055.15. According to 12 analysts rating.

Source: S&P Global Market Intelligence

Alembic Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹1,046.5
    Day's Price Range
    ₹1,081.9

  • 52 Week's Low

    52 Week's High

    ₹746
    52-Week Price Range
    ₹1,303.9
1 Month Return+ 0.96 %
3 Month Return-10.08 %
1 Year Return+ 38.83 %
Previous Close₹1,047.80
Open₹1,047.80
Volume3.04L
Upper Circuit-
Lower Circuit-
Market Cap₹20,761.00Cr

Alembic Pharmaceuticals Ltd Key Statistics

P/E Ratio32.4
PEG Ratio6.12
Market Cap₹20,761.00 Cr
P/B Ratio3.93
EPS31.33
Dividend Yield1.12
SectorPharmaceuticals
ROE14.3

Alembic Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd
HOLD₹20,761.00 Cr18.71%0.55₹615 Cr₹6,228 Cr
Sanofi India Ltd
Sanofi India Ltd
BUY₹14,100.35 Cr-2.24%0.52₹602 Cr₹2,851 Cr
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
BUY₹73,098.77 Cr33.6%0.56₹3,168 Cr₹29,001 Cr
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
HOLD₹98,565.65 Cr55.28%0.64₹3,854 Cr₹19,547 Cr
Abbott India Ltd
Abbott India Ltd
BUY₹59,732.90 Cr24.06%0.53NANA
See all

Alembic Pharmaceuticals Ltd Mutual Fund Holdings

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals is a leading generic pharmaceuticals manufacturer and marketer based in India. Established in 2010 as a subsidiary of Alembic Ltd., they stopped being a subsidiary in 2011 when they were allotted 133515914 equity shares of Rs 2 each to their shareholders. In 2014 Alembic Pharmaceuticals entered into a joint venture with Adwiya Mami SARL, Algeria and in 2015 an exclusive agreement was signed with Novartis. In 2016, Alembic Pharmaceuticals formed Aleor Dermaceuitical Limited in a 60:40 joint venture with Orbicular and a state-of-the-art anticancer manufacturing facility opened in Gujarat in 2017. One year later Alembic Pharmaceuticals completed the acquisition of Orit Laboratories LLC, a generic drug developer, along with real estate. In 2018 Alembic Pharmaceuticals was inspected by the US FDA and were issued with 3 observations. In 2019, they launched 9 new products in the US, and the novel Umbralicib UKONIQ was licensed by TG Therapeutics USA in 2021. In 2022, Aleor Dermaceuticals was amalgamated into Alembic Pharmaceutical and became a wholly owned subsidiary.

Share Price: ₹1055.15 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹20,761.00Cr as of today
Revenue: ₹1,647.98Cr as on September 2024 (Q3 24)
Net Profit: ₹153.14Cr as on September 2024 (Q3 24)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
OrganisationAlembic Pharmaceuticals Ltd
HeadquartersVadodara
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Alembic Pharmaceuticals Ltd

  • Alembic Pharma Secures USFDA Approval for Key Drug - 20 Dec, 2024

    Alembic Pharmaceuticals announced final USFDA approval for Divalproex Sodium Delayed-Release Capsules, a significant addition to its portfolio, with a market size of $61.1 million.

  • Alembic Pharma Issues $10 Million Guarantee - 18 Dec, 2024

    Alembic Pharmaceuticals Ltd has issued a corporate guarantee of $10 million in favor of HSBC Bank, Chile, to support its subsidiary Alembic Pharmaceuticals SpA.

  • Alembic Pharma Achieves Audit Success and Profit Growth - 11 Dec, 2024

    Alembic Pharmaceuticals successfully completed a GMP audit by ANVISA for its API-II facility in Brazil. The company reported a 12% increase in net profit for Q2 FY25, attributed to strong growth in specialty and animal health segments.

  • Alembic Pharma Dissolves Six Subsidiaries for Restructuring - 09 Dec, 2024

    Alembic Pharmaceuticals has dissolved six step-down subsidiaries, including Okner Realty LLC and Alembic Labs LLC, as part of its restructuring efforts to streamline operations.

  • Alembic Pharmaceuticals Dissolves Non-Operational Subsidiaries - 06 Dec, 2024

    Alembic Pharmaceuticals Ltd. announced the dissolution of six non-operational step-down subsidiaries, including Okner Realty LLC and Alembic Labs LLC, as per regulatory requirements.

  • Alembic Pharmaceuticals Secures USFDA Approval for Eye Drops - 04 Dec, 2024

    Alembic Pharmaceuticals announced tentative USFDA approval for its Olopatadine Hydrochloride Ophthalmic Solution, a generic equivalent to Alcon's Pataday. The market size is estimated at $22 million.

  • Alembic Pharma Faces USFDA Observations at Facility - 25 Nov, 2024

    Alembic Pharmaceuticals received five procedural observations from the USFDA during a GMP inspection of its Gujarat facility. The company is committed to addressing these observations and maintaining quality standards.

Insights on Alembic Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 134.71 Cr → 153.41 Cr (in ₹), with an average increase of 12.2% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, APLLTD stock has moved up by 1.0%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 1.52K Cr → 1.67K Cr (in ₹), with an average increase of 4.8% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 8.05% to 8.90% in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 135.8% return, outperforming this stock by 97.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 57.1% return, outperforming this stock by 21.4%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 69.61% of holdings in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 10.60% to 10.39% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 4.32% to 3.94% in Sep 2024 quarter

Alembic Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹1,594.93Cr (-)₹1,630.57Cr (↑2.23%)₹1,516.98Cr (↓6.97%)₹1,561.73Cr (↑2.95%)₹1,647.98Cr (↑5.52%)
Net Income₹136.56Cr (-)₹180.45Cr (↑32.14%)₹178.21Cr (↓1.24%)₹134.54Cr (↓24.50%)₹153.14Cr (↑13.82%)
Net Profit Margin8.56% (-)11.07% (↑29.32%)11.75% (↑6.14%)8.61% (↓26.72%)9.29% (↑7.90%)
Value in ₹ crore
Details2021202220232024
Total Assets₹6,786.27Cr (-)₹7,225.33Cr (↑6.47%)₹6,213.56Cr (↓14.00%)₹6,529.82Cr (↑5.09%)
Total Liabilities₹1,684.46Cr (-)₹1,934.99Cr (↑14.87%)₹1,799.26Cr (↓7.01%)₹1,620.91Cr (↓9.91%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹539.75Cr (-)₹1,388.48Cr (↑157.25%)₹545.26Cr (↓60.73%)₹730.25Cr (↑33.93%)₹772.77Cr (↑5.82%)

Index Inclusions

BSE Healthcare

₹44,095.46

-1.13 (▲-505.02%)

BSE 500

₹35,082.25

-1.9 (▲-680.42%)

Nifty 500

₹22,319.40

-1.9 (▲-432.75%)

Nifty Smallcap 250

₹17,693.65

-2.01 (▲-363.55%)

S&P BSE 400 MidSmallCap

₹12,101.72

-2.24 (▲-276.79%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

S&P BSE 250 SmallCap

₹7,054.81

-2.03 (▲-146.24%)

BSE Small-Cap

₹55,149.22

-2.11 (▲-1188.47%)

Nifty MidSmallcap 400

₹19,899.40

-2.27 (▲-461.95%)

Alembic Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
69.61%
0.00
Foreign Institutions
3.94%
-8.68
Mutual Funds
8.9%
10.53
Retail Investors
10.39%
-1.98
Others
7.16%
-3.54

Alembic Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Return On Assets %13.8316.897.215.59.43
Details20202021202220232024
Book Value Per Share (₹)170.79257.8266.47222.36245.14
Details20202021202220232024
Earning Per Share (₹)42.4756.7226.517.431.33
Details20202021202220232024
Return On Equity %3225.9610.467.1514.3

Alembic Pharmaceuticals Ltd Valuation

Alembic Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (11.53x)

March 23, 2020

Today (32.40x)

December 19, 2024

Industry (56.23x)

December 19, 2024

Highest (53.41x)

January 3, 2023

LowHigh

Alembic Pharmaceuticals Ltd Earnings and Dividends

  • Alembic Pharmaceuticals Ltd Earnings Results

    Alembic Pharmaceuticals Ltd’s net profit jumped 12.34% since last year same period to ₹153.41Cr in the Q2 2024-2025. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated 13.88% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Alembic Pharmaceuticals Ltd Dividends May,2024

    In the quarter ending March 2024, Alembic Pharmaceuticals Ltd has declared dividend of ₹11 - translating a dividend yield of 1.04%.

    Read More about Dividends

Alembic Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Alembic Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

FAQs on Alembic Pharmaceuticals Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Alembic Pharmaceuticals Ltd shares.

Alembic Pharmaceuticals Ltd (APLLTD) share price today is ₹1055.15

Alembic Pharmaceuticals Ltd is listed on NSE

Alembic Pharmaceuticals Ltd is listed on BSE

  • Today’s highest price of Alembic Pharmaceuticals Ltd is ₹1081.9.
  • Today’s lowest price of Alembic Pharmaceuticals Ltd is ₹1046.5.

PE Ratio of Alembic Pharmaceuticals Ltd is 32.4

PE ratio = Alembic Pharmaceuticals Ltd Market price per share / Alembic Pharmaceuticals Ltd Earnings per share

Today’s traded volume of Alembic Pharmaceuticals Ltd(APLLTD) is 3.04L.

Today’s market capitalisation of Alembic Pharmaceuticals Ltd(APLLTD) is ₹20761Cr.

Alembic Pharmaceuticals Ltd(APLLTDPrice
52 Week High
₹1303.9
52 Week Low
₹746

Alembic Pharmaceuticals Ltd(APLLTD) share price is ₹1055.15. It is down -19.08% from its 52 Week High price of ₹1303.9

Alembic Pharmaceuticals Ltd(APLLTD) share price is ₹1055.15. It is up 41.44% from its 52 Week Low price of ₹746

Alembic Pharmaceuticals Ltd(APLLTDReturns
1 Day Returns
7.35%
1 Month Returns
0.96%
3 Month Returns
-10.08%
1 Year Returns
38.83%